Immuno-oncology continues to transform treatment landscapes as checkpoint inhibitors move into new markets, earlier lines of therapy and combinations. Early data presented at the American Society of Clinical Oncology annual meeting suggest that as PD-1/L1 inhibitors move into first-line metastatic renal cell carcinoma, Pfizer Inc.'s targeted therapy Inlyta may be the partner of choice.
Immuno-Oncology Outlook Series
The first in Scrip's series on cancer immunotherapy expanding
Inlyta (axitinib), the follow-on to Pfizer's Sutent (sunitinib), has been established for use after one prior line of systemic therapy in metastatic renal cell carcinoma (mRCC), following approval in August 2014. But FDA approval of three new drugs for mRCC in recent years has raised questions about positioning in the future – Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo (nivolumab), Eisai Co. Ltd.'s multi-TKI Lenvima (lenvatinib) and Exelixis Inc.'s Cometriq (cabozantinib), also a multi-target TKI (see box)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?